{"id":"W3168849811","doi":"10.1111/bjh.17448","title":"Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study","year":2021,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hotel Dieu Hospital","funders":"Merck","keywords":"Carfilzomib; Medicine; Pembrolizumab; Dexamethasone; Daratumumab; Multiple myeloma; Cohort; Oncology; Refractory (planetary science); Lenalidomide; Internal medicine; Cancer; Immunotherapy; Materials science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00308181,0.002328712,0.002882795,0.0003518633,0.0006426883,0.002063523,0.001529448,0.001833335,0.006046149],"category_scores_gemma":[0.00203599,0.0008212739,0.003483025,0.0006015985,0.0007093354,0.001175469,0.0006729247,0.004112229,0.001788488],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002251499,"about_ca_system_score_gemma":0.002984395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002770366,"about_ca_topic_score_gemma":0.005430308,"domain_scores_codex":[0.9991388,0.0003317728,0.00004951164,0.0002104334,0.0001052179,0.0001642347],"domain_scores_gemma":[0.9989029,0.0001194065,0.0002855257,0.0001317217,0.0001099022,0.000450526],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8810565,0.03084757,0.01486571,0.001642051,0.00673717,0.0002618106,0.0002464516,0.001449512,0.009049877,0.0003448831,0.01181919,0.04167929],"study_design_scores_gemma":[0.7569187,0.1866476,0.03374985,0.0002604901,0.004926166,0.0004718288,0.0001348525,0.0009033019,0.001833332,0.000386117,0.01368727,0.00008041925],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9514174,0.01172088,0.001127974,0.001975165,0.000592873,0.009966784,0.01784931,0.0001532022,0.005196484],"genre_scores_gemma":[0.9365411,0.008379877,0.003234902,0.004234291,0.000980643,0.01103167,0.02923147,0.0001096688,0.006256343],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006046149,"threshold_uncertainty_score":0.02022636,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0307628737725269,"score_gpt":0.3139515126887084,"score_spread":0.2831886389161815,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}